Like other macrolide antibiotics, azithromycin inhibits protein synthesis by penetrating the cell wall and binding to the 50S ribosomal subunits in susceptible bacteria. It is considered a bacteriostatic antibiotic. Azithromycin has a relatively broad spectrum. It has _in vitro_ activity (does not necessarily indicate clinical efficacy) against gram-positive organisms such as _Streptococcus pneumoniae_, _Staph_ _aureus_ ; gram-negative organisms such as _Haemophilus_ _influenzae_ ; _Bordetella_ spp.; and _Mycoplasma_ _pneumoniae_, _Borrelia_ _burgdorferi_ and _Toxoplasma_ spp.
Azithromycin with its relative broad spectrum and favorable pharmacokinetic profile may be useful for a variety of infections in veterinary species. Little data is published at this time, however. Azithromycin has been shown to be ineffective in the treatment of _Mycoplasma haemofelis_ in cats. Azithromycin may be potentially useful for treating Rhodococcus infections in foals.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
僅在精確動物物種與年齡、體重與器官功能、診斷與病原證據、培養或敏感性、治療目的、精確產品與濃度、併用方案、監測、抗菌管理、法規與處方治理均完整且經獸醫人工確認後，才可另行評估是否建立可執行合約；目前一律不執行。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。